Napredna pretraga

Pregled bibliografske jedinice broj: 625109

Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy

Cesarec, Vedran; Bečejac, Tomislav; Mišić, Marija; Djaković, Željko; Olujić, Danijela; Drmić, Domagoj; Brčić, Luka; Stančić Rokotov , Dinko; Seiwerth, Sven; Sikirić, Predrag
Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy // European journal of pharmacology, 701 (2013), 1/3; 203-212 doi:10.1016/j.ejphar.2012.11.055 (međunarodna recenzija, članak, znanstveni)

Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy

Cesarec, Vedran ; Bečejac, Tomislav ; Mišić, Marija ; Djaković, Željko ; Olujić, Danijela ; Drmić, Domagoj ; Brčić, Luka ; Stančić Rokotov , Dinko ; Seiwerth, Sven ; Sikirić, Predrag

European journal of pharmacology (0014-2999) 701 (2013), 1/3; 203-212

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
BPC 157 ; Esophagus ; Fistula ; NO-system ; eNOS ; Rats

Esophagocutaneous fistulas are a failure of the NO-system, due to NO-synthase blockage by the NOS-blocker L-NAME consequently counteracted by l-arginine and gastric pentadecapeptide BPC 157 (l-arginine <BPC 157), precipitating a therapeutic benefit. Previously, there was an established BPC 157-NO-system interaction. BPC 157 GEPPPGKPADDAGLV, MW 1419 (LD1 not achieved), is a safe and stable anti-ulcer peptide, successful in inflammatory bowel disease trials, counteracting esophagitis, sphincter failure, gastrointestinal and skin ulcers, gastrocutaneous or colocutaneous fistulas. We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination. RT-PCR investigated eNOS, iNOS, COX-2 mRNA levels in the fistulas. We evidenced a closely inter-related process of unhealed skin, esophageal defects, unhealed fistulas (up regulated eNOS, iNOS and COX2 mRNA levels), usually lethal, particularly NO-system related and therapy dependent. Generally, the course of fistula healing was accelerated either to a greater extent (with BPC 157 (in particular, less eNOS gene expression) completely counteracting L-NAME effects, in L-NAME+BPC 157 and L-NAME+l-arginine+BPC 157 groups), or to a lesser extent (with l-arginine). Conversely, the process was aggravated, rapidly and prominently (with L-NAME). In particular, BPC 157 was effective either given per-orally/intraperitoneally, in μg- and ng-regimens. Shortly, defects started to heal, with less fistula leakage and no mortality at day 4. Failure of pyloric and lower esophageal sphincter pressure was restored, with practically no esophagitis.

Izvorni jezik

Znanstvena područja
Temeljne medicinske znanosti


Projekt / tema
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Predrag Sikirić, )
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Sven Seiwerth, )

Medicinski fakultet, Zagreb

Časopis indeksira:

  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus

Uključenost u ostale bibliografske baze podataka:

  • BIOSIS Previews (Biological Abstracts)
  • CA Search (Chemical Abstracts)
  • EMBASE (Excerpta Medica)
  • Elsevier BIOBASE
  • Pascal et Francis (INST-CNRS)
  • Reference Update
  • Scopus
  • Unlisted Drugs